Kemwell Biopharma has added a 7,500 sq ft cGMP pilot plant to complement its commercial-scale production facility in Bangalore, India.
Opening of the development facility, which is located next to commercial-scale manufacturing assets, gives Kemwell capabilities for handling formulation of a range of dosage forms. Kemwell says demand for these services has grown.
“We are seeing an increasing demand for contract development services in the global market”, Anurag Bagaria, managing director at Kemwell, said. Kemwell employs 80 scientists at the lab but can scale-up to a headcount of 150 if demand continues to grow.